IL1B and breast cancer: The current study suggests that BC ACN may mitigate the risk of CVD in peri- and early postmenopausal women through improving blood lipids, inflammation, and lipid peroxidation as indicated by decreasing trends in blood TG, IL-1β, and TBARS levels in a dose-dependent manner, and significant inverse correlations between six-month changes in CAT and TAC with oxLDL.